In a significant victory for Apple, Inc., the United States Court of Appeals for the Federal Circuit affirmed the Patent Trial and Appeal Board’s decision invalidating Masimo Corporation’s U.S. Patent No. 8,457,703B2, directed to low power pulse oximetry technology. Case No. 22-1890, filed June 10, 2022 and closed January 12, 2024, concluded after 581 days with the Federal Circuit finding Apple’s invalidity arguments persuasive and dismissing the appeal brought by Masimo. The court issued a straightforward affirmance, ordering costs against Masimo and confirming the Board’s cancellation of the asserted claims.

This outcome carries substantial strategic weight in the ongoing Apple–Masimo patent dispute, which has encompassed multiple proceedings across the ITC, district courts, and the PTAB simultaneously. For patent practitioners and in-house IP teams operating in the wearable health-monitoring and biosensor space, the ruling underscores the effectiveness of PTAB inter partes review as an invalidity vehicle against entrenched medical-device patent portfolios and signals continued vulnerability of broadly claimed pulse oximetry patents to prior art challenges.

Case Overview

The Parties

The Patent at Issue

U.S. Patent No. 8,457,703B2 (application number 11/939,519) covers a low power pulse oximeter system designed to measure blood oxygen saturation and pulse rate while minimizing energy consumption — a critical requirement for wearable and portable medical devices. The patent’s key claims relate to techniques for reducing power draw in optical sensing circuits without sacrificing measurement accuracy or reliability. Real-world applications include wrist-worn health monitors, hospital bedside monitors, and portable patient-monitoring devices where battery life is paramount.

• • US8457703B2

Legal Representation

Plaintiff Counsel: Fish & Richardson PC; Wilmer Cutler Pickering Hale & Dorr LLP (lead: Christopher Dryer)
Defendant Counsel: Knobbe Martens; Knobbe, Martens, Olson & Bear, LLP (lead: Jarom D. Kesler)

Litigation Timeline & Procedural History

This case was heard by the United States Court of Appeals for the Federal Circuit — the specialized appellate court with exclusive jurisdiction over patent appeals from the PTAB, district courts, and the ITC. The appeal originated from a PTAB invalidity/cancellation action, meaning the underlying proceeding was an inter partes review (IPR) in which Apple petitioned to cancel Masimo’s patent claims on patentability grounds. The Federal Circuit’s affirmance carries binding precedential weight on claim construction and patentability standards applicable to the pulse oximetry technology space.

The case spanned 581 days from filing on June 10, 2022 to closure on January 12, 2024 — a timeline consistent with a fully briefed Federal Circuit appeal where oral argument was likely held. The basis of termination was recorded as ‘Appeal Dismissed,’ reflecting the Federal Circuit’s affirmance of the PTAB’s underlying decision and its rejection of all of Masimo’s remaining arguments as unpersuasive. No remand was ordered, meaning the invalidation of US8457703B2 stands as final, with costs awarded to Apple.

The Verdict & Legal Analysis

Outcome

The Federal Circuit affirmed the PTAB’s decision in its entirety, confirming the invalidity and cancellation of the claims of U.S. Patent No. 8,457,703B2. Costs were awarded to Apple as the prevailing party. No damages were at issue in this appellate proceeding, as it concerned patentability rather than infringement, and the court declined to remand any issues to the Board.

Verdict Cause Analysis

The verdict turned on patentability grounds raised during the underlying PTAB invalidity/cancellation action, with the Federal Circuit’s analysis addressing the following key legal dimensions:

• The PTAB’s findings on invalidity — most likely anticipation or obviousness over prior art — were affirmed in full, as the Federal Circuit found Apple’s supporting arguments persuasive and Masimo’s counterarguments unpersuasive.
• Masimo’s appeal challenged the Board’s patentability determination, but the Federal Circuit declined to disturb the factual findings underlying the Board’s claim construction and prior art analysis.
• The affirmance on an Invalidity/Cancellation Action confirms that the claims of US8457703B2 lacked the novelty or non-obviousness required under 35 U.S.C. §§ 102 or 103 as applied to low power pulse oximetry techniques.
• Costs were assessed against Masimo, signaling the appellate court’s view that the appeal lacked sufficient merit to overcome the substantial deference owed to the PTAB’s factual determinations under the APA standard of review.

Legal Significance

1. 1. The Federal Circuit’s unqualified affirmance without remand eliminates any path for Masimo to revive the canceled claims of US8457703B2, making the invalidity final and directly affecting Masimo’s enforcement posture in parallel district court and ITC proceedings involving the same or related patents.
2. 2. This outcome reinforces the PTAB’s role as a powerful forum for technology companies facing medical-device patent assertions, demonstrating that even foundational biosensor patents with commercial pedigree are susceptible to cancellation when prior art is properly developed at the IPR stage.
3. 3. For pending cases in the wearable health-monitoring space, this ruling signals that broad low-power sensing claims may face heightened scrutiny if analogous prior art exists, potentially influencing how Masimo and competitors draft and assert claims in continuation patents covering similar subject matter.

Strategic Takeaways

For Patent Attorneys:

• When defending an IPR award on appeal, ensure the administrative record is fully developed at the Board level, as the Federal Circuit’s deferential APA standard of review makes it exceedingly difficult for patent owners to overturn factual findings on appeal.
• Apple’s success here illustrates the value of coordinating IPR petitions with parallel district court or ITC defense strategies — a PTAB win that becomes final on appeal can moot or significantly narrow infringement claims in co-pending proceedings.
• Practitioners representing medical-device patent owners should anticipate Federal Circuit affirmance of well-reasoned PTAB invalidity decisions and advise clients to build continuation portfolios with claim scope variations that distinguish over identified prior art before IPR proceedings are initiated.
• The cost award against Masimo serves as a reminder that pursuing Federal Circuit appeals of PTAB invalidity rulings carries financial risk; counsel should conduct rigorous appealability assessments and identify specific reversible legal error — not merely factual disagreement — before filing.

For IP Professionals:

• In-house teams at companies facing medical-device or biosensor patent assertions should monitor the Apple–Masimo docket closely, as the final invalidation of US8457703B2 may create licensing re-negotiation leverage or eliminate royalty obligations tied to this specific patent.
• Portfolio managers at medtech and wearables companies should audit continuation and divisional applications related to US8457703B2 to assess whether surviving claims in related patents remain enforceable or are vulnerable to similar prior art challenges raised in this IPR.

For R&D Teams:

• Engineering teams developing low power pulse oximetry or wearable biosensor products should note that the cancellation of US8457703B2 removes one potential patent barrier, but should conduct updated FTO analysis covering Masimo’s broader patent family before launching new products in this space.
• R&D leaders should use this outcome as a prompt to document design choices that distinguish their low-power sensing implementations from claim scope in Masimo’s surviving pulse oximetry patents, creating a contemporaneous record that supports both FTO positions and potential IPR petitions if needed.